<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567306</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-PHL-P2-001</org_study_id>
    <secondary_id>2011-000814-21</secondary_id>
    <nct_id>NCT01567306</nct_id>
  </id_info>
  <brief_title>Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense</brief_title>
  <official_title>Phase II, Multicenter, Randomized, Double Blind Study, With Subcutaneous Immunotherapy At Different Doses, in Parallel Groups and Placebo-Controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Phleum Pratense</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on EMA (European Medicines Agency) new guidelines on the clinical development of
      products for immunotherapy for the treatment of allergic diseases the aim of this study is to
      establish a dose-response relationship for clinical efficacy of Phleum pratense pollen
      extract subcutaneous vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In adherence to EMA guidelines, the Phase I Clinical trial was carried out using Phleum
      pratense extract in depot presentation using 3 different dose escalation scheme. The
      objective was to compare tolerance and safety of the three dose escalation scheme as well as
      to determine the maximum dose tolerated by the population.

      Once the range of tolerated doses was established, and following the strict norms of the EMA,
      a Phase II dose response clinical trial was designed wherein the efficacy of subcutaneous
      immunotherapy in depot presentation could be compared in 5 different doses. One of these
      doses will be the MTD established by the population in the first study, another will be lower
      than this dose, and three will be greater than it. The dose escalation scheme to be tested
      was chosen based on the results of the aforementioned clinical trial. As dictated by EMA
      norms, a control placebo will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV).</measure>
    <time_frame>Baseline (V0) and Final Visit (FV). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. The study will be carried out outside the pollination season of Phleum pratense.</time_frame>
    <description>Variation of the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). The changes will be compared among groups (including the placebo group).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Adverse Reactions and or Events Will be Recorded Both by the Patient and the Health Care Personnel Responsible for the Administration of the Subcutaneous Immunotherapy.</measure>
    <time_frame>From baseline (V0) to final visit (VF). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. All AE should be monitored until they are satisfactorily resolved or stabilized after the final visit of the study</time_frame>
    <description>All adverse reactions and/or events were recorded both by the patient and the health care personnel responsible for the administration of the subcutaneous immunotherapy. The incidence and intensity of adverse events was compared among the treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Allergovac Depot Group 1 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac Depot Group 2 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac Depot Group 3 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac Depot Group 4 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac Depot Group 5 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Depot</intervention_name>
    <description>Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Allergovac Depot Group 1 Active</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Depot</intervention_name>
    <description>Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Allergovac Depot Group 2 Active</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Depot</intervention_name>
    <description>Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Allergovac Depot Group 3 Active</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Depot</intervention_name>
    <description>Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Allergovac Depot Group 4 Active</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Depot</intervention_name>
    <description>Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Allergovac Depot Group 5 Active</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
    <arm_group_label>Placebo - Group 6</arm_group_label>
    <other_name>Allergovac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must sign the Informed Consent Form.

          2. Patients must be between 18 and 60 years of age.

          3. Patients with seasonal allergic rhinoconjunctivitis produced by Phleum pratense during
             at least 2 years prior to participating in the study. Although the pathology being
             studied is allergic rhinoconjunctivitis, patients who have concomitant mild or
             moderate asthma may be included.

          4. Patients who have had a skin prick test result equal or more than 3 mm in diameter
             against Phleum pratense.

          5. Patients who have specific IgE equal or more than class 2 (CAP/PHADIA) to Phleum
             pratense.

          6. Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients
             may only be included in the study if their other sensitizations are produced by:

               -  Overlapping seasonal pollens which are cross-reactive with Phleum pratense.

               -  Pollens whose seasons do not overlap with Phleum pratense and which are not
                  expected to produce symptoms during the study period.

               -  Other allergens which are not expected to produce symptoms during the study
                  period.

          7. Women of child-bearing potential must have a negative urine pregnancy test at the time
             they begin the study.

          8. Furthermore, women of child-bearing potential must agree to use adequate contraceptive
             methods during this study if they are sexually active.

        Exclusion Criteria:

          1. Patients with stable and continued use of allergy medication during the 2 weeks prior
             to their inclusion in the study.

          2. Patients sensitized to allergens with overlapping seasons but which are not
             cross-reactive with Phleum pratense and with specific IgE levels equal or less than
             class 2 CAP/PHADIA.

          3. Patients who have received immunotherapy in the 5 years prior to the study against
             either the allergen being tested or an allergen which is cross-reactive, or who are
             currently receiving immunotherapy for any other allergen.

          4. Patients with severe asthma or FEV1 &lt; 70% or with asthma which requires treatment with
             inhaled or systemic corticoids at the time of the study or in the 8 weeks immediately
             prior to the onset of treatment.

          5. Patients with immunological, cardiac, renal or hepatic diseases or any with any other
             illness which the investigators deem may interfere with the study.

          6. Patients with a prior history of anaphylaxis.

          7. Patients with chronic urticaria.

          8. Patients with moderate-severe atopic dermatitis.

          9. Patients with clinically relevant malformations of the upper respiratory tract.

         10. Patients who have participated in another clinical trial within 3 months prior to this
             study.

         11. Patients being treated with tricyclic antidepressants, psychotropic drugs,
             beta-blockers, or angiotensin-converting enzyme inhibitors (ACEIs).

         12. Women who are pregnant or breast-feeding or are of child-bearing age and who do not
             agree to use adequate contraception if they are sexually active and who have not
             demonstrated that they have been surgically sterilized or have other means of not
             bearing children.

         13. Patients who cannot attend study visits.

         14. Patients who are uncooperative or refuse to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Alvarez Cuesta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santiago Quirce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matilde Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Manuel Zubeldia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Panizo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ntra. Sra. del Prado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>João Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto CUF Porto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luís Plácido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar de S. João</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Alberto Ferreira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar Gaia/Espinho</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Celso Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital da Universidade de Coimbra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filipe Inácio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar de Setúbal - Hospital de São Bernardo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de S. João</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto CUF Porto</name>
      <address>
        <city>Senhora da Hora</city>
        <zip>4460-188</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Setúbal - Hospital de São Bernardo</name>
      <address>
        <city>Setúbal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Gaia/Espinho</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ntra. Sra. del Prado</name>
      <address>
        <city>Talavera de la Reina</city>
        <state>Toledo</state>
        <zip>45600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>August 9, 2018</results_first_submitted>
  <results_first_submitted_qc>January 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2019</results_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Allergic rhinoconjunctivitis</keyword>
  <keyword>Subcutaneous Immunotherapy</keyword>
  <keyword>Phleum pratense pollen extract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allergovac Depot Group 1 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="P2">
          <title>Allergovac Depot Group 2 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="P3">
          <title>Allergovac Depot Group 3 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="P4">
          <title>Allergovac Depot Group 4 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="P5">
          <title>Allergovac Depot Group 5 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="P6">
          <title>Placebo - Group 6</title>
          <description>Placebo: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change site living</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allergovac Depot Group 1 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B2">
          <title>Allergovac Depot Group 2 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B3">
          <title>Allergovac Depot Group 3 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B4">
          <title>Allergovac Depot Group 4 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B5">
          <title>Allergovac Depot Group 5 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B6">
          <title>Placebo - Group 6</title>
          <description>Placebo: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="7.7"/>
                    <measurement group_id="B2" value="31.8" spread="9.9"/>
                    <measurement group_id="B3" value="34.8" spread="9.0"/>
                    <measurement group_id="B4" value="33.5" spread="9.4"/>
                    <measurement group_id="B5" value="34.9" spread="8.3"/>
                    <measurement group_id="B6" value="35.0" spread="10"/>
                    <measurement group_id="B7" value="32.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV).</title>
        <description>Variation of the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). The changes will be compared among groups (including the placebo group).</description>
        <time_frame>Baseline (V0) and Final Visit (FV). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. The study will be carried out outside the pollination season of Phleum pratense.</time_frame>
        <population>Intent-to-treat population (ITT): This population included all randomized patients who received at least one treatment dose and who presented baseline and post-baseline values for the primary efficacy variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Allergovac Depot Group 1 Active</title>
            <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Allergovac Depot Group 2 Active</title>
            <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
          <group group_id="O3">
            <title>Allergovac Depot Group 3 Active</title>
            <description>Allergovac Depot: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
          <group group_id="O4">
            <title>Allergovac Depot Group 4 Active</title>
            <description>Allergovac Depot: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
          <group group_id="O5">
            <title>Allergovac Depot Group 5 Active</title>
            <description>Allergovac Depot: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
          <group group_id="O6">
            <title>Placebo - Group 6</title>
            <description>Placebo: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV).</title>
          <description>Variation of the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). The changes will be compared among groups (including the placebo group).</description>
          <population>Intent-to-treat population (ITT): This population included all randomized patients who received at least one treatment dose and who presented baseline and post-baseline values for the primary efficacy variable.</population>
          <units>SPT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.493" spread="2.060"/>
                    <measurement group_id="O2" value="0.275" spread="2.884"/>
                    <measurement group_id="O3" value="0.693" spread="2.142"/>
                    <measurement group_id="O4" value="0.876" spread="2.414"/>
                    <measurement group_id="O5" value="1.385" spread="2.170"/>
                    <measurement group_id="O6" value="0.839" spread="2.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Adverse Reactions and or Events Will be Recorded Both by the Patient and the Health Care Personnel Responsible for the Administration of the Subcutaneous Immunotherapy.</title>
        <description>All adverse reactions and/or events were recorded both by the patient and the health care personnel responsible for the administration of the subcutaneous immunotherapy. The incidence and intensity of adverse events was compared among the treatment groups.</description>
        <time_frame>From baseline (V0) to final visit (VF). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. All AE should be monitored until they are satisfactorily resolved or stabilized after the final visit of the study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each participant in the research, the treatment duration was established at 17 weeks, of which 5 weeks were needed for the induction phase and the other 12 weeks were for treatment at the maintenance dose. During this period adverse event data were collected.</time_frame>
      <desc>Any unfavorable medical occurrence, including any abnormal sign (for example, abnormal physical exam), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participation in the research.
Adverse reactions were classified as local or systemic in relation to where the reaction appeared. Local reactions appeared in the same place of administration and systemic reactions occurred far from the administration point.</desc>
      <group_list>
        <group group_id="E1">
          <title>Allergovac Depot Group 1 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="E2">
          <title>Allergovac Depot Group 2 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="E3">
          <title>Allergovac Depot Group 3 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="E4">
          <title>Allergovac Depot Group 4 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="E5">
          <title>Allergovac Depot Group 5 Active</title>
          <description>Allergovac Depot: Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
        <group group_id="E6">
          <title>Placebo - Group 6</title>
          <description>Placebo: Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>cutaneous pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>generalized pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinitis allergic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small simple size, the strong placebo effect and patients without a positive result with any of the tested vials at the final visit were assigned the vial 4 value for analysis purposes, meaning no real improvement could be observed in patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. M Cruz Gómez project manager of Roxall Medicina España S.A.</name_or_title>
      <organization>Roxall Medicina España S.A.</organization>
      <phone>+34 944438000</phone>
      <email>maricruz.gomez@roxall.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

